Dyslipidemias are common after renal transplantation. Causes of dyslipidemia are usage of multiple immunosuppressives (especially prednisolone, cyclosporine and sirolimus), graft dysfunction (reduced glomeruler filtration rate and proteinuria) and genetic predisposition. In this study, the effects of cyclosporine (CsA), tacrolimus (Tac) and sirolimus on lipid profile of our patients at Akdeniz University Organ Transplantation Center are investigated and compared with each other. We included 47 renal transplant patients (male/female: 32/15), mean age of these patients was 35.7 ± 9.3 year (range: 23-60). Donor type of renal transplant patients were living-related (n=32) and cadeveric (n=15). Twenty renal transplant patients were using prednisolone+MMF+CsA (Grup 1), other 20 renal transplant patients were using prednisolone+MMF+Tac (Grup 2), and the rest of the renal transplant patients (n=7) were using prednisolone+MMF+sirolimus (Grup 3). We investigated serum cholesterol and triglyceride levels before and after transplantation at the 1., 3., 6. and 12. months. The cholesterol levels before renal transplantation ranged between 104-310 mg/dl (mean cholesterol level: 165.5±42.5), triglyceride levels ranged between 50-473 mg/dl (mean triglyceride level: 146±88.5). When we compared cholesterol levels at the 3rd month of renal transplantation between group 1 and group 2, it was found that cholesterol levels in group1 were higher than group 2 (p=0.02). Triglyceride levels at the 12 th month of renal transplantation in group 1 were also higher than group 2. The cholesterol and triglyceride levels between group 1 and 3 did not show any statistical significance. Cholesterol levelsl at the 1st and 3rd months of renal transplantation in group 3 were significantly higher than cholesterol levels in group 2. These results showed that regarding dyslipidemia, tacrolimus is a safer drug compared to CsA and sirolimus.